Tonix's TONMYA reaches $15M, but a $163M cash pile and a Paragraph IV filing frame the debate
Third-quarter net product revenue rose to about $17.2M, yet opex of $72.7M and a runway only into early Q3 2027 mean financing and patent litigation loom over the launch.
The quarter in numbers
Tonix Pharmaceuticals reported third-quarter 2026 net product revenue of approximately $17.2 million, against $3.3 million a year earlier. TONMYA, the fibromyalgia treatment launched on November 17, 2025, contributed approximately $15.0 million. The older migraine products, Zembrace SymTouch and Tosymra, contributed approximately $2.2 million, down from $3.3 million in the third quarter of 2025. Nine-month product revenue was $37.7 million, versus $7.7 million in the same period of 2025.
The company said TONMYA net sales were up 37% from the second quarter. Operating loss was $55.4 million, compared with $33.1 million a year earlier. Net loss available to common stockholders was $53.3 million, or $2.89 per share, against $32.0 million, or $3.59 per share. The per-share loss narrowed even as the dollar loss widened because weighted average shares roughly doubled, to 18,440,773 from 8,922,792.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Sources
- Tonix Pharmaceuticals Holding Corp.: quarterly results release (SEC filing) SEC EDGAR · 09 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. Earnings analysis is based on the company's results release filed with the SEC, not on the earnings call. It can contain errors; check the sources. Not investment advice.
ADC Therapeutics: volume-led sales and deeper cost cuts, as recapitalisation shifts focus to ASH
Q3 net product revenue of $21.0M and a 29% cut in adjusted opex narrowed the loss, while an October restructuring extended the company's expected cash runway into 2029.
Inhibrx's Q3: Debt and launch prep push losses up as chondrosarcoma review looms
A $2.0 million Pfizer licence fee barely dented a $38.7 million net loss as interest costs and pre-commercial spend rose while R&D fell and the balance sheet moved into deficit.
Talphera's Q3: no revenue, a smaller per-share loss and an FDA bet on early NEPHRO enrollment close
With $14.2 million in cash and a pivotal CRRT study running short of its 70-patient target, Talphera is asking the FDA to accept a December 31, 2026 enrollment cutoff.